241 related articles for article (PubMed ID: 28138258)
1. Chidamide in the treatment of peripheral T-cell lymphoma.
Chan TS; Tse E; Kwong YL
Onco Targets Ther; 2017; 10():347-352. PubMed ID: 28138258
[TBL] [Abstract][Full Text] [Related]
2. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
[TBL] [Abstract][Full Text] [Related]
3. Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China.
Shi Y; Jia B; Xu W; Li W; Liu T; Liu P; Zhao W; Zhang H; Sun X; Yang H; Zhang X; Jin J; Jin Z; Li Z; Qiu L; Dong M; Huang X; Luo Y; Wang X; Wang X; Wu J; Xu J; Yi P; Zhou J; He H; Liu L; Shen J; Tang X; Wang J; Yang J; Zeng Q; Zhang Z; Cai Z; Chen X; Ding K; Hou M; Huang H; Li X; Liang R; Liu Q; Song Y; Su H; Gao Y; Liu L; Luo J; Su L; Sun Z; Tan H; Wang H; Wang J; Wang S; Zhang H; Zhang X; Zhou D; Bai O; Wu G; Zhang L; Zhang Y
J Hematol Oncol; 2017 Mar; 10(1):69. PubMed ID: 28298231
[TBL] [Abstract][Full Text] [Related]
4. Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study.
Gao Y; He H; Li X; Zhang L; Xu W; Feng R; Li W; Xiao Y; Liu X; Chen Y; Wang X; Bai B; Wu H; Cai Q; Li Z; Li J; Lin S; He Y; Ping L; Huang C; Mao J; Chen X; Zhao B; Huang H
Signal Transduct Target Ther; 2024 May; 9(1):121. PubMed ID: 38755119
[TBL] [Abstract][Full Text] [Related]
5. Development of chidamide for peripheral T-cell lymphoma, the first orphan drug approved in China.
Lu X; Ning Z; Li Z; Cao H; Wang X
Intractable Rare Dis Res; 2016 Aug; 5(3):185-91. PubMed ID: 27672541
[TBL] [Abstract][Full Text] [Related]
6. Chidamide tablets: HDAC inhibition to treat lymphoma.
Xu Y; Zhang P; Liu Y
Drugs Today (Barc); 2017 Mar; 53(3):167-176. PubMed ID: 28447074
[TBL] [Abstract][Full Text] [Related]
7. A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China.
Liu W; Zhao D; Liu T; Niu T; Song Y; Xu W; Jin J; Cai Q; Huang H; Li Z; Hou M; Zhang H; Zhou J; Hu J; Shen J; Shi Y; Yang Y; Zhang L; Zhao W; Ding K; Qiu L; Tan H; Zhang Z; Liu L; Wang J; Xu B; Zhou H; Gao G; Xue H; Bai O; Feng R; Huang X; Yang H; Yan X; Zeng Q; Liu P; Li W; Mao M; Su H; Wang X; Xu J; Zhou D; Zhang H; Ma J; Shen Z; Zhu J
Front Oncol; 2021; 11():750323. PubMed ID: 34804937
[TBL] [Abstract][Full Text] [Related]
8. Aberrant JAK-STAT signaling-mediated chromatin remodeling impairs the sensitivity of NK/T-cell lymphoma to chidamide.
Chen J; Zuo Z; Gao Y; Yao X; Guan P; Wang Y; Li Z; Liu Z; Hong JH; Deng P; Chan JY; Cheah DMZ; Lim J; Chai KXY; Chia BKH; Pang JWL; Koh J; Huang D; He H; Sun Y; Liu L; Liu S; Huang Y; Wang X; You H; Saraf SA; Grigoropoulos NF; Li X; Bei J; Kang T; Lim ST; Teh BT; Huang H; Ong CK; Tan J
Clin Epigenetics; 2023 Feb; 15(1):19. PubMed ID: 36740715
[TBL] [Abstract][Full Text] [Related]
9. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified.
Ji MM; Huang YH; Huang JY; Wang ZF; Fu D; Liu H; Liu F; Leboeuf C; Wang L; Ye J; Lu YM; Janin A; Cheng S; Zhao WL
Haematologica; 2018 Apr; 103(4):679-687. PubMed ID: 29305415
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas.
Dong M; Ning ZQ; Xing PY; Xu JL; Cao HX; Dou GF; Meng ZY; Shi YK; Lu XP; Feng FY
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1413-22. PubMed ID: 22362161
[TBL] [Abstract][Full Text] [Related]
11. Chidamide (CS055/HBI-8000): a new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicity.
Ning ZQ; Li ZB; Newman MJ; Shan S; Wang XH; Pan DS; Zhang J; Dong M; Du X; Lu XP
Cancer Chemother Pharmacol; 2012 Apr; 69(4):901-9. PubMed ID: 22080169
[TBL] [Abstract][Full Text] [Related]
12. Chidamide in combination with chemotherapy in refractory and relapsed T lymphoblastic lymphoma/leukemia.
Guan W; Jing Y; Dou L; Wang M; Xiao Y; Yu L
Leuk Lymphoma; 2020 Apr; 61(4):855-861. PubMed ID: 31755348
[TBL] [Abstract][Full Text] [Related]
13. Effect of chidamide on treating hepatosplenic T-cell lymphoma: A case report.
Wang XT; Guo W; Sun M; Han W; Du ZH; Wang XX; Du BB; Bai O
World J Clin Cases; 2020 Jul; 8(14):3122-3129. PubMed ID: 32775395
[TBL] [Abstract][Full Text] [Related]
14. Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
Wang Y; Zhang M; Song W; Cai Q; Zhang L; Sun X; Zou L; Zhang H; Wang L; Xue H
Am J Hematol; 2022 May; 97(5):623-629. PubMed ID: 35170082
[TBL] [Abstract][Full Text] [Related]
15. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results.
Rai S; Kim WS; Ando K; Choi I; Izutsu K; Tsukamoto N; Yokoyama M; Tsukasaki K; Kuroda J; Ando J; Hidaka M; Koh Y; Shibayama H; Uchida T; Yang DH; Ishitsuka K; Ishizawa K; Kim JS; Lee HG; Minami H; Eom HS; Kurosawa M; Lee JH; Lee JS; Lee WS; Nagai H; Shindo T; Yoon DH; Yoshida S; Gillings M; Onogi H; Tobinai K
Haematologica; 2023 Mar; 108(3):811-821. PubMed ID: 36200417
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a sensitive HPLC-MS/MS method for determination of chidamide (epidaza), a new benzamide class of selective histone deacetylase inhibitor, in human plasma and its clinical application.
Gu R; Liu T; Zhu X; Gan H; Wu Z; Li J; Zheng Y; Dou G; Meng Z
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Sep; 1000():181-6. PubMed ID: 26245362
[TBL] [Abstract][Full Text] [Related]
17. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-γ response in NK-T cell lymphoma.
Wen T; Sun G; Jiang W; He X; Shi Y; Ma F; Liu P
EBioMedicine; 2023 Jan; 87():104420. PubMed ID: 36592514
[TBL] [Abstract][Full Text] [Related]
18. Forodesine in the treatment of relapsed/refractory peripheral T-cell lymphoma: an evidence-based review.
Makita S; Maeshima AM; Maruyama D; Izutsu K; Tobinai K
Onco Targets Ther; 2018; 11():2287-2293. PubMed ID: 29719411
[TBL] [Abstract][Full Text] [Related]
19. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
Apuri S; Sokol L
Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
[TBL] [Abstract][Full Text] [Related]
20. Chidamide based combination regimen for treatment of monomorphic epitheliotropic intestinal T cell lymphoma following radical operation: Two case reports.
Liu TZ; Zheng YJ; Zhang ZW; Li SS; Chen JT; Peng AH; Huang RW
World J Clin Cases; 2020 Apr; 8(7):1278-1286. PubMed ID: 32337203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
